We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04634825
Recruitment Status : Terminated (Based on internal review of safety data)
First Posted : November 18, 2020
Last Update Posted : November 7, 2022
Sponsor:
Information provided by (Responsible Party):
MacroGenics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : July 29, 2022
Actual Study Completion Date : July 29, 2022